Long-Acting b 2 -Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma

Author Affiliations and Financial Disclosures are listed at the end of this article. Corresponding Author and Reprints: Stephen C. Lazarus, MD, University of California, San Francisco, 505 Parnassus Ave, San Francisco, CA 94143-0111 (e-mail: lazma@itsa.ucsf.edu). Context Long-acting b2-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs). No evidence exists, however, to support their use as monotherapy in adults with persistent asthma.

[1]  E. Israel,et al.  Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. , 2001, JAMA.

[2]  F. Thien,et al.  An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. , 1999, American journal of respiratory and critical care medicine.

[3]  S. Yancey,et al.  A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  P. Howarth,et al.  The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[5]  M. Sears,et al.  Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.

[6]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[7]  S. Wenzel,et al.  The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. , 1997, Chest.

[8]  L. Boulet,et al.  INFLUENCE OF SALMETEROL ON CHRONIC AND ALLERGEN-INDUCED AIRWAY INFLAMMATION IN MILD ALLERGIC ASTHMA: A PILOT STUDY , 1997 .

[9]  Arthur S Slutsky,et al.  Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. , 1997, American journal of respiratory and critical care medicine.

[10]  R. Roorda,et al.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. , 1997, American journal of respiratory and critical care medicine.

[11]  D. Postma,et al.  Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups. , 1996, Chest.

[12]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[13]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[14]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[15]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[16]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[17]  G. Alonzo.  Salmeterol Xinafoate As Maintenance Therapy Compared With Albuterol in Patients With Asthma. , 1994 .

[18]  H. Boushey,et al.  Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: a method for studying allergic airway inflammation. , 1994, The Journal of allergy and clinical immunology.

[19]  S. Pedersen,et al.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. , 1994, Respiratory medicine.

[20]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[21]  G. Guyatt,et al.  Measuring quality of life in asthma. , 1993, The American review of respiratory disease.

[22]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[23]  E. Bleecker,et al.  The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation , 1992 .

[24]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[25]  C. Page.  One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by β2-agonists , 1991, The Lancet.

[26]  C. Newth,et al.  Viewpoint: untoward effects of beta-adrenoceptor agonists in asthma. , 1990, The European respiratory journal.

[27]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[28]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.